The use of ACE inhibitors during SLE is generally well tolerated and associated with a delay in the onset of renal involvement and a decline in the risk of disease relapse in SLE patients [26] that likely occurs from both the decrease in angiotensin II and the immunomodulatory impact of renin-angiotensin system blockade. The gene discussed is ACE; the disease is systemic lupus erythematosus.